© 2020 MJH Life Sciences and OncLive. All rights reserved.
October 21, 2019
Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.
September 10, 2019
Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.
September 04, 2019
Douglas K. Marks, MD, clinical instructor, Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, discusses the role of TKIs in HER2-positive breast cancer.